Pro-Dex Inc. (PDEX)
NASDAQ: PDEXHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PDEX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $201.60M
- P/E (TTM)
- 17.36
- Forward P/E
- 18.16
- EPS (TTM)
- $3.63
- Dividend yield
- None
- 52-week range
- 32.14 – 77.00
- Day range
- 61.96 – 63.55
- Volume / Avg
- 53.56K / 54.15K
- Beta
- —
- Shares outstanding
- 3.20M
52-week range
PDEX stock today
Pro-Dex (PDEX) closed at $63.00 on Nov 20, down 0.77% (-$0.49), versus the S&P 500's 3.70% decline. Shares are 18.2% below their 52-week high of $77.00, set on Sep 4, 2026 and 96.0% above the 52-week low of $32.14, in the middle of the past year's range. PDEX is up 63.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 92.9%.
Pro-Dex trades at 17.4x its trailing twelve-month earnings per share of $3.63. Its forward P/E of 18.2x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Pro-Dex
Company profilePro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Richard Lee Van Kirk Jr.
- Headquarters
- Irvine, CA
- Employees
- 201
- Website
- pro-dex.com
Financial highlights
Full financialsIn fiscal 2026, Pro-Dex generated $77.5 million in revenue, up 16.5% from fiscal 2025, its 13th consecutive year of revenue growth. Net income was $13.7 million (+52.2% year over year), for a net margin of 17.6% versus a median of 13.5% in the prior 5 years. Gross margin was 31.4% (up from 29.3%) and operating margin 16.8%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $77.55M | $66.59M | $53.84M | $46.09M | $42.04M |
| Growth | +16.45% | +23.68% | +16.83% | +9.62% | +10.55% |
| Net income | $13.66M | $8.98M | $2.13M | $7.07M | $4.57M |
| EPS (diluted) | $4.12 | $2.67 | $0.60 | $1.95 | $1.21 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$80.00+26.98%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.92 vs $0.67
- Surprise
- +37.31%
PDEX news
All PDEX news- Align Technology (ALGN) Beats Q3 Earnings and Revenue EstimatesNasdaqALGN, PDEX
- ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?NasdaqPDEX, EW, GMED, GKOS
- Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDexNasdaqBDX, CAH, MCK, MMSI
- 5 Medical Dental Supply Stocks to Watch as Industry Prospects ImproveNasdaqMCK, BDX, CAH, MMSI
Pro-Dex peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KTWOK2 Capital Acquisition Corporation Class A | 10.13 | 0.00% | $203.02M | vs PDEX |
| UTMDUtah Medical Products Inc. | 69.49 | -2.07% | $198.01M | vs PDEX |
| CLPTClearPoint Neuro Inc. | 6.91 | -5.47% | $221.49M | vs PDEX |
| ANIKAnika Therapeutics Inc. | 13.23 | -0.38% | $177.22M | vs PDEX |
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs PDEX |
| OSUROraSure Technologies Inc. | 3.46 | -4.16% | $238.90M | vs PDEX |
| OFIXOrthofix Medical Inc. | 6.07 | -4.26% | $247.41M | vs PDEX |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs PDEX |
Indexes, lists and sector
Pro-Dex stock FAQ
What is Pro-Dex's stock price today?
PDEX last traded at $63.00 as of Nov 20, 4:00 PM EST, down 0.77% on the day. Prices are delayed at least 15 minutes.
Does Pro-Dex pay a dividend?
No. Pro-Dex does not currently pay a regular cash dividend.
What is PDEX's P/E ratio?
PDEX trades at a trailing P/E ratio of 17.36 and a forward P/E of 18.16.
Who is Pro-Dex's CEO?
Mr. Richard Lee Van Kirk Jr. is the chief executive officer of Pro-Dex Inc., which has about 201 employees.
Has PDEX ever split its stock?
Yes. The most recent PDEX stock split was a 1-for-3 split on Jun 18, 2010.
What is the PDEX 52-week high?
The 52-week high for PDEX is $77.00 and the 52-week low is $32.14. The stock is currently 18.2% below its high.